ABSTRACT
Standard treatment strategy for acute cardiogenic pulmonary edema includes noninvasive positive pressure ventilation as an alternative treatment for patients with acute cardiogenic pulmonary edema who require endotracheal intubation. Even in the improvement of hypoxemia, the beneficial effects depend on preload and afterload reduction with positive pressure ventilation. Although several strategies have been proposed for mask fitting problems, patient dependent ventilation mask compliance is one of the major critical problems. In our institution, intravenous morphine hydrochloride has been used for load reduction and sedative effects in such patients, achieving favorable clinical outcomes.
Subject(s)
Heart Failure/complications , Intermittent Positive-Pressure Ventilation , Morphine/administration & dosage , Pulmonary Edema/therapy , Acute Disease , Aged , Aortic Valve Prolapse/complications , Humans , Infusions, Intravenous , Intubation, Intratracheal , Male , Mitral Valve Prolapse/complications , PrognosisABSTRACT
CASE REPORT: We report a pregnant patient with adenocarcinoma in situ (AIS) coexisting with carcinoma in situ (CIS) of the cervix diagnosed by conization at 16 weeks' gestation. Apoptotic activity was higher in the CIS lesion than in the AIS lesion in the cone biopsy specimen. Postpartum evaluation confirmed the disappearance of CIS lesion with positive cone margins, however, multifocal AIS with negative cone margins was found. CONCLUSION: Clinical course and biological features of AIS associated with pregnancy may be different from those of CIS.
Subject(s)
Adenocarcinoma/diagnosis , Carcinoma in Situ/diagnosis , Neoplasms, Multiple Primary/diagnosis , Pregnancy Complications, Neoplastic/diagnosis , Uterine Cervical Neoplasms/diagnosis , Adenocarcinoma/pathology , Adenocarcinoma/surgery , Adult , Apoptosis , Carcinoma in Situ/pathology , Carcinoma in Situ/surgery , Cerclage, Cervical , Colposcopy , Conization , Female , Gestational Age , Humans , Hysterectomy , Immunohistochemistry , In Situ Nick-End Labeling , Laser Therapy , Neoplasms, Multiple Primary/pathology , Neoplasms, Multiple Primary/surgery , Pregnancy , Pregnancy Complications, Neoplastic/pathology , Pregnancy Complications, Neoplastic/surgery , Uterine Cervical Neoplasms/pathology , Uterine Cervical Neoplasms/surgeryABSTRACT
PURPOSE: To evaluate the efficacy and toxicity of a novel combination treatment using concurrent radiotherapy with cisplatin plus UFT, which is comprised of uracil and tegafur, in locally advanced non-small cell lung cancer (NSCLC) patients. EXPERIMENTAL DESIGN: In this Phase II trial, patients with unresectable stage III NSCLC were treated with the oral administration of UFT (400 mg/m(2)/d tegafur) on days 1-14 and days 29-42 whereas 80 mg/m(2) cisplatin was administered i.v. on days 8 and 36. Radiotherapy, with a total dose of 60 Gy, was delivered in 30 fractions from day 1. RESULTS: Seventy patients were enrolled and eligible, as follows: 57 males/13 females; mean age 61 ranging from 36 to 74; performance status 0/1:45/25; stage IIIA/IIIB, 14/56. A complete response was observed in two patients and a partial response in 54 patients, and the overall response rate was 81% (95% confidence interval; 70-89%). The median survival, the 1- and 2-year survival rates were 16.5 months, 67% and 33%, respectively. Grade 3/4 leukopenia occurred in 14%/1% of the patients. Grades 3 non-hematological toxicities were only reported in three patients with nausea, two with esophagitis and one with pneumonitis whereas no grade 4 non-hematological toxicity was observed. CONCLUSIONS: UFT plus cisplatin with concurrent radiotherapy is considered to be a feasible and effective treatment for locally advanced NSCLC patients. Additional study of this concurrent chemoradiotherapy is warranted.
